25724-79-2 Usage
General Description
1-Oxo-2,3-dihydro-1H-indene-5-carbonitrile is a chemical compound that belongs to the class of indene derivatives. It is also known by its CAS number 112662-14-9. 1-OXO-2,3-DIHYDRO-1H-INDENE-5-CARBONITRILE contains a carbonyl group, a nitrile group, and a six-membered ring structure. It is commonly used as an intermediate in the synthesis of various pharmaceuticals, agrochemicals, and organic compounds. 1-OXO-2,3-DIHYDRO-1H-INDENE-5-CARBONITRILE has potential applications in drug discovery and material science due to its unique chemical structure and reactivity. It is important to handle this chemical with caution as it may pose health and environmental risks if not properly managed.
Check Digit Verification of cas no
The CAS Registry Mumber 25724-79-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,5,7,2 and 4 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 25724-79:
(7*2)+(6*5)+(5*7)+(4*2)+(3*4)+(2*7)+(1*9)=122
122 % 10 = 2
So 25724-79-2 is a valid CAS Registry Number.
InChI:InChI=1/C10H7NO/c11-6-7-1-3-9-8(5-7)2-4-10(9)12/h1,3,5H,2,4H2
25724-79-2Relevant articles and documents
INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS
-
Page/Page column 128, (2021/09/11)
The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
CARDIAC SARCOMERE INHIBITORS
-
Paragraph 0245, (2020/01/24)
Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, Y1, Y2, L1, and G1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
Aromatic ring functionalization of benzolactam derivatives: New potent dopamine D3 receptor ligands
Ortega, Raquel,Hübner, Harald,Gmeiner, Peter,Masaguer, Christian F.
supporting information; experimental part, p. 2670 - 2674 (2011/06/20)
Since the discovery of the dopamine D3 receptor, an intensive effort has been directed toward the development of potent and selective ligands in order to elucidate the function and potential therapeutic advantages of targeting D3 rec
